KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer

Summary

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with relapsed or refractory small cell lung cancer. This study will be conducted in 2 parts. Part 1 will evaluate two treatment arms, each with a different KRT-232 dose. Part 2 will continue the evaluation of the selected treatment arms from Part 1.

Timeline

Start

2021-12-06

Primary completion

2022-08-26

Completion

2022-08-26

Outcome

Outcome not reported

Stopped: “Unanticipated and extremely high screen failure rate. There was no evidence of safety concerns in the study.”

Drugs

Indications